Welcome to Markets Desk, here's what's moving markets this Wednesday.
The AI spending boom is facing a harder crowd. Elice's dramatic stock swings this week signal that investors are no longer willing to take data center buildout on faith. The question shifting across trading desks is whether billions in infrastructure spending will actually convert to durable, scalable profit — and the market is demanding answers now.
Shifting to pharma, GSK scored a meaningful regulatory win as the FDA approved Hibsago, its treatment for chronic hepatitis B in adults. The drug works in combination with existing antiviral therapy, targeting a patient population that has had limited curative options for years. Approval clears a significant commercial runway for GSK heading into the back half of the year.
And in Asia overnight, Tokyo's Nikkei two twenty five climbed back above sixty four thousand seven hundred, snapping a two-session losing streak. Exporters led the recovery, aided by yen dynamics and a steadier tone from Wall Street. Financial stocks also contributed meaningfully, suggesting the bounce carries some breadth rather than just sector rotation.
That's the tape. Markets Desk, signing off the floor.
